How long to give dostarlimab for untreated rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests different lengths of treatment with the drug dostarlimab for people with a specific type of rectal cancer that has a high number of genetic mutations. The goal is to find the best duration of treatment to improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer that is stage II or III, meaning it has grown into the bowel wall or spread to nearby lymph nodes, but has not spread to distant organs.
- Your tumor has a specific genetic feature called dMMR or MSI-H, which means it has trouble repairing its DNA. This can be found with a simple test on a biopsy sample.
- You are able to perform daily activities without help (performance status 0 or 1).
- Your organs are functioning well enough to receive the treatment.
- You have not had prior treatment for rectal cancer, such as radiation, chemotherapy, or surgery.
- You do not have an active autoimmune disease that required treatment in the last 2 years, and you are not currently taking other cancer treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach: giving the immunotherapy drug dostarlimab along with a short course of radiation before surgery, with the goal of avoiding surgery in many patients. It is for people with a specific type of rectal cancer (MSI-H or dMMR) that has not spread to other organs.
This trial studies dostarlimab given around the time of colon cancer surgery for people with untreated, resectable (operable) stage T4N0 or stage III colon cancer that has specific tumor markers. It may help shrink or eliminate the cancer before or after surgery by boosting the immune response.
This trial tests a drug called dostarlimab for people with certain advanced cancers that have a specific genetic feature (dMMR/MSI-H). The goal is to see if it helps shrink or control the cancer in people who haven't had other treatments yet.
This study looks at how well the immunotherapy drug dostarlimab works before surgery in patients with a specific type of advanced rectal cancer that has DNA repair problems (called dMMR/MSI-H). The goal is to see if it is safe and effective in the real world.
This Phase 2 trial studies dostarlimab (an immune therapy that targets PD-1) given before surgery or other initial treatment. It aims to shrink certain locally advanced cancers that have mismatch repair deficiency, potentially making treatment easier and improving outcomes.
This trial tests a drug called dostarlimab for people with a specific type of stomach cancer that has not spread. The goal is to see if the drug can make the tumor disappear, so you might not need surgery right away.
Hear when a new Neoplasms, Rectal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.